All In Biotech

Drug Trial Radar · NCT03658772

Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

An Open-label, Single-arm, Phase 1b Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembolizumab in Patients With Advanced or Progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Last checked: Nov 20, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Sep 20, 2018

Primary completion

Mar 7, 2023

Study completion Mar 7, 2023

Sponsor

Lead sponsor
Arrys TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted in adult participants diagnosed with any form of an advanced or progressive MSS CRC for which 1st and 2nd line standard therapy (at least one of which contained fluorouracil) is no longer effective or is intolerable. This is a phase 1b, multi-center, open label study designed to assess safety and tolerability of grapiprant in combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with pembrolizumab, and to evaluate and characterize the PK of grapiprant alone and in combination with pembrolizumab. Disease response, pharmacodynamics, and response biomarkers will also be assessed.

Conditions

  • Microsatellite Stable Colorectal Cancer

Interventions

  • grapiprantDrug

    Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.

  • grapiprant and pembrolizumabDrug

    Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of grapiprant alone and in combination with pembrolizumabTime frame: Up to 90 days after the end of treatment (average of 7 months)
  2. Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumabTime frame: Through Cycle 1 (21 days)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center - Scottsdale

    Phoenix, Arizona

  • University of Colorado Denver-Anschutz Medical Campus

    Aurora, Colorado

  • Sarah Cannon Research Institute, LLC (SCRI)

    Nashville, Tennessee

  • New Experimental Therapeutics of San Antonio-NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.